In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Subscribe To Our Newsletter & Stay Updated
